Related Experiment Video

Updated: Mar 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Dendrimer-Based Selective Proteostasis-Inhibition Strategy to Control NSCLC Growth and Progression

Kyla Walworth1, Manish Bodas1, Ryan John Campbell1

  • 1College of Medicine, Central Michigan University, Mount Pleasant, Michigan, United States of America.

Plos One
|July 20, 2016
PubMed

Insights

Dendrimer-encapsulated valosin-containing protein (VCP) inhibitor DBeQ effectively controls non-small cell lung cancer (NSCLC) progression by inhibiting proteostasis. This targeted delivery enhances VCP inhibition, leading to reduced tumor growth and increased apoptosis in NSCLC cells.

Area of Science:

  • Oncology
  • Nanotechnology
  • Biochemistry

Background:

  • Elevated valosin-containing protein (VCP/p97) levels are implicated in non-small cell lung carcinoma (NSCLC) progression.
  • Existing VCP inhibitors often lack specificity, limiting targeted tumor cell delivery.

Purpose of the Study:

  • To evaluate the in vitro efficacy of a dendrimer-encapsulated VCP inhibitor for controlling NSCLC progression.
  • To assess the targeted delivery and therapeutic potential of dendrimer-encapsulated DBeQ in NSCLC cells.

Main Methods:

  • In vitro assessment of VCP inhibitor efficacy (DBeQ vs. NMS-873) in H1299 NSCLC cells.
  • Evaluation of proliferation, migration, invasion, apoptosis, and cell cycle progression.
  • Utilized MTT assay, scratch assay, caspase-3/7 assay, immunoblotting, immunostaining, and clonogenic assay.

Main Results:

  • Dendrimer-encapsulated DBeQ (DDNDBeQ) significantly decreased NSCLC cell proliferation, migration, and invasion.
  • DDNDBeQ treatment increased apoptosis and induced G2/M cell cycle arrest.
  • DDNDBeQ effectively inhibited VCP-mediated proteostasis, evidenced by increased ubiquitinated-protein accumulation.

Conclusions:

  • Encapsulation of DBeQ into dendrimers enables selective VCP-mediated proteostasis inhibition.
  • DDNDBeQ demonstrates potent in vitro efficacy in controlling NSCLC tumor growth and progression.
  • This approach offers potential for tumor-targeted sustained drug delivery in NSCLC therapy.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.5K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K